Necrotizing enterocolitis (NEC), the most common surgical emergency in newborns, remains a therapeutic challenge for clinicians. The hematological manifestations associated with NEC were first described 25 years ago. This review discusses current knowledge of the pathophysiology involved in disturbances in megakaryocytopoiesis, coagulation, leukopoiesis, and erythropoiesis that accompany the clinical entity NEC. The discussion includes current understanding of and potential strategies for treating the hematopoietic disturbances that occur secondary to NEC.
INTRODUCTION
The devastating disease, necrotizing enterocolitis (NEC), a disease of the gastrointestinal tract, has multiple systemic clinical manifestations, including severe hematopoietic disturbances. The disease is complex, without unifying etiology, but epidemiological observations emphasize the roles of gastrointestinal immaturity, infection, abnormal intestinal bacterial colonization, inflammation, enteric feeding, and gastrointestinal vascular compromise. 1, 2 Despite major advances in understanding the multisystem pathophysiology of NEC, treatment of NEC remains largely supportive. The hematological abnormalities associated with NEC were first described 25 years ago by Hutter et al. 3 The abnormalities observed in a series of 40 patients with NEC included thrombocytopenia, with and without disseminated intravascular coagulation (DIC), neutrophilia or neutropenia, and hemolytic anemia. 3 Since 1976, an impressive expansion of knowledge has improved the understanding of cellular mechanisms behind disturbed hematopoiesis accompanying the disease, NEC. However, this knowledge has not been translated into decreased morbidity and mortality from NEC. Massive blood product administration continues to be necessary to effectively treat the severe hematopoietic disturbances in NEC. Although not all deaths seen with NEC are from hematological complications, these complications contribute significantly to NEC mortality. As investigators commonly include patients with NEC in studies of infants with sepsis, and as gastrointestinal infection and sepsis are both significant contributors to the pathology of NEC, we have included data from studies of sepsis, as well as studies of NEC. The scope of this review will examine current understanding of the disturbances in hematopoiesis in NEC and not every aspect of this complex disease (see Table 1 ). The review will discuss the current and potential treatment for hematopoietic disturbances and preventative strategies that may result in improved hematopoiesis.
PLATELETS Platelet Number
Infants with severe NEC develop thrombocytopenia. [3] [4] [5] Lower platelet counts have been reported to be associated with greater disease severity. In the description by Hutter et al. 3 of the 40 initial patients, mean platelet nadir was 46,500±58,400 in those who died, compared to 69,300±640,000/mm 3 in survivors. In a 1977 study by Patel, 4 20/23 nonsurvivors exhibited platelet counts less than 150,000/mm 3 while 12/24 survivors were thrombocytopenic. A recent review reports that the incidence of thrombocytopenia in NEC is 65% to 90%, 6 unchanged from the earliest reports. 3, 4 In survivors, the median time to recovery to a platelet count greater than 150,000/mm 3 was 7 to 10 days. 3, 4 Thrombocytopenia is also common with any neonatal infection. Current data support that approximately 80% of neonates diagnosed with any infection (not necessarily NEC) exhibit platelet counts less than 150,000/mm 3 , while 55% to 65% exhibit counts less than 100,000/mm 3 , with counts depressed for a mean of 6 days. 6 Bacterial sepsis in premature infants <1500 g birth weight is associated with a 70% incidence of moderate-to-severe thrombocytopenia.
Pathophysiology of Thrombocytopenia
Although the minority of patients with NEC exhibit documented DIC with thrombocytopenia, data support that platelet consumption rather than decreased production is the major contributor to thrombocytopenia. From the initial two reports, bone marrow obtained from seven infants at autopsy showed normal megakaryocyte number and maturation. 3, 4 In NEC, platelet counts may fall rapidly (within hours), a finding that supports consumption rather than decreased production. In neonates, platelet counts rapidly fall in response to inflammation/infection, hypoxia, or acidosis, all of which commonly accompany NEC. 8 As therapeutic platelet transfusions in NEC are commonly associated with only a short-lived (24 to 48 hours) rise in platelet count, this observation supports that consumption of the transfused platelets is also seen. 6 Recent data describing the cellular mechanisms behind the development of NEC also support that platelet consumption is responsible for thrombocytopenia. Platelet activating factor (PAF) is implicated in the gastrointestinal pathology of NEC. [9] [10] [11] [12] PAF is an inflammatory, phospholipid cytokine contributing to the bowel necrosis seen in experimental NEC. 9 Compared to adults, neonatal gastrointestinal tissue has a relatively greater capacity for producing PAF. 6 Plasma PAF levels rise after exposure to hypoxia in a model of bowel necrosis in young rats. 9 In a study of serial plasma PAF levels in NICU admissions, PAF and PAF-related lipids were higher in infants diagnosed with NEC than those without the diagnosis. 13 Plasma PAF levels rose with severity of NEC and a PAF cutoff value of 10.2 ng/ml for NEC exhibited a positive predictive value of 100%. 13 Human milk contains high levels of active PAFacetylhydrolase, the enzyme that breaks down PAF.
14 Human milk feeding of premature infants has been demonstrated to prevent NEC. 14, 15 In rats, experimental NEC is prevented by concurrent administration of exogenous PAF-acetylhydrolase 11 or PAF receptor antagonists. 9, 10 Although PAF universally stimulates platelet activation, no rat or human studies reported simultaneous PAF and peripheral platelet counts. However, experimental LPS administration to human volunteers results in a rapid fall in platelet counts. After LPS infusion, platelet counts fell within an hour, immature reticulated platelets rose 5 hours later, and plasma thrombopoietin (Tpo) levels rose at 24 hours. 16 Although other hematopoietic growth factors are involved in megakaryocyte production, Tpo, interleukin-6 (IL-6), and IL-11 are the critical growth factors necessary for committed megakaryocyte maturation. [17] [18] [19] Stool and peritoneal IL-6 levels were elevated in infants with NEC. 20 Plasma IL-6 levels were relatively high in neonatal sepsis or NEC, but were markedly higher in the combination of sepsis and NEC. 19 Plasma IL-6 levels were also higher in NEC nonsurvivors vs survivors. 19 These findings support that platelet consumption is a major cause of thrombocytopenia in NEC. IL-11 has trophic effects on bowel. 21 There are no reports of plasma IL-11 levels in neonates or ill neonates, but intestinal IL-11 mRNA levels were higher in those with NEC, compared to those with other bowel inflammatory diseases. 22 Patients with NEC, but without bowel perforation, had the highest levels of intestinal IL-11 mRNA. 22 Additional support for platelet destruction in neonatal sepsis comes from the finding that circulating levels of macrophage colony stimulating factor (M-CSF), which are known to be associated with platelet destruction, are higher in septic neonates and inversely correlate with platelet counts. 23 Chronic depression of platelet production may play a lesser role in thrombocytopenia associated with NEC. Tpo is the major hormone stimulating platelet production throughout development. 24 Tpo is a glycoprotein hormone with structural homology to erythropoietin (Epo). 24 Circulating levels of Tpo were high in cord blood and the first days of postnatal life, 25 but were relatively lower in thrombocytopenic neonates vs thrombocytopenic adults. 25, 26 Serum Tpo levels in neonates were variable, but tended to be lower in sepsis or infection, 27, 28 suggesting an inability to upregulate Tpo production in response to thrombocytopenia associated with these conditions. Data support that plasma Tpo levels in thrombocytopenic neonates are blunted in response to low platelet counts, similar to relatively low plasma Epo levels in the anemia of prematurity. 6 Monitoring Platelet Number, Size, and Function Following serial platelet counts may help guide surgical therapy, as data support that indications for surgery include perforation of the bowel, portal venous gas, or persistent/worsening thrombocytopenia. 29 Although one study showed that in relatively mature infants (greater than 34 weeks gestation at birth), lower platelet counts at the presentation of NEC predicted which infants ultimately required surgical treatment of NEC, 30 other sources supported that falling platelet counts over the first 24 hours were associated with those who ultimately required surgery. [29] [30] [31] In a recent retrospective review, platelet counts of less than 100 Â 10 9 /l or a fall in serial platelet counts were poor prognostic indicators of intestinal gangrene. 32 Nadir platelet counts were lower in nonsurvivors, compared to survivors, as well as lower in those with panintestinal disease, compared to less severe disease. 32 Positive predictive values for intestinal gangrene were 89% when two consecutive platelet counts less than 100 Â 10 9 /l were observed and 92% when a rapid fall (greater than 150 Â 10 9 /l fall in 24 hours) was observed. 32 Immature platelets, similar to immature erythrocytes, are larger in size and are reticulated. 6 These parameters can routinely be measured with the advanced flow cytometry cell counters available in clinical laboratories. In states of platelet destruction, mean platelet volume (MPV) rises, presumably because younger platelets are replacing older, destroyed platelets. In neonates, MPV greater than 10.8 fl is 95% sensitive for diagnosis of neonatal bacteremia, although increased MPV is not specific and may also occur in the genetic disorder, 22q11 deletion (velocardiofacial syndrome). 33 Evaluation of platelet function in neonates is fraught with difficulty. As bleeding times are influenced by variability in technique, and may be prolonged after administration of common neonatal medications (indomethacin, intralipid infusions, and ampicillin), 34, 35 utility of the bleeding time measurement in neonates is limited. Similar to adults, the bleeding time in healthy and ill neonates is inversely related to platelet number. 34 No published study has addressed whether sepsis or NEC is associated with a greater prolongation of bleeding time that the fall in platelet count would support. Traditional laboratory tests to monitor platelet function are limited secondary to their semiquantitative nature and difficulty in standardization. Newer techniques using whole-blood flow cytometry may show promise secondary to improved sensitive and increased ability for quantitative comparisons. 36 Treating Thrombocytopenia In the original study by Hutter et al., 3 infants exhibited a variable response to platelet transfusions, with some infants exhibiting a rise in count while others exhibiting no change. In the second series, transfusions were administered in 12/47 patients, with no description of change. 4 In NEC, therapeutic response to platelet transfusions is commonly short-lived. 6 Indications for platelet transfusion are variable and are based on limited specific data. Indications for transfusion should be based on the presence of clinical bleeding, potential risks of bleeding, as well as the severity of thrombocytopenia. Hematopoietic cytokines have been studied as a treatment option in other populations of thrombocytopenic patients. IL-11 administration stimulates megakaryocyte production and increases platelet counts in adults undergoing myelosuppression, 6 however, no clinical trials treating neonates with IL-11 have been performed. An experimental murine model of bowel necrosis showed that IL-11 administration is associated with improved survival, more rapid intestinal mucosal recovery, and increased peripheral platelet counts. 21 Therapy with recombinant Tpo has been studied in adult populations and neonatal animals, reviewed in Sola et al., 6 but no data are currently available in premature infants. Although both Tpo and IL-11 are currently in clinical trials for other conditions, platelet transfusions are given early in the course of neonatal NEC and/or sepsis and data support that 3 to 6 days are necessary for the rise in platelet counts observed after growth factor therapy. 6 Perhaps treatment with Tpo and/or IL-11 may be useful for decreasing number of platelet transfusions in those requiring multiple transfusions over 7 to 10 days. Melatonin, which works as a free radical scavenger, given to a small number of term infants with sepsis has been associated with higher platelet counts within 24 to 48 hours after treatment. 37 Thrombocytopenia contributes to morbidity and mortality of NEC and is a poor prognostic sign. Evidence supports that platelet destruction is the major contributor to thrombocytopenia in NEC, although depressed platelet production may also contribute. Treatment of thrombocytopenia remains supportive, with platelet transfusions commonly ineffective. Although studies are incomplete, cytokine therapy might warrant ongoing investigation.
COAGULATION DISTURBANCES Pathophysiology of Coagulation Disturbances
In neonates, development of the hemostatic process is dynamic and is influenced by both gestational and postnatal age. 8 At birth, plasma levels and activities of most coagulation proteins are low (25% to 50% of adult levels). 8 Likewise, most inhibitors of coagulation and fibrinolytic proteins are also lower at birth. 8 Despite the deficiencies of procoagulant, regulatory, and fibrinolytic activities, these processes seem balanced in healthy term children. However, in ill premature infants, minimal reserve capacity results in major imbalances. In severe infections and shock, the host defenses increase tissue factor activity, release cytokines, and modulate coagulation and fibrinolytic systems, ultimately resulting in DIC. 38 In the initial study by Hutter et al., 3 14 infants were evaluated for DIC. Six of 14 infants had decreased plasma fibrinogen levels, with a subset having evidence of fibrin split products or elevated partial thromboplastin times. In a study by Patel, 4 the diagnosis of DIC was more common in infants who died of NEC (15/23 vs 4/24 survivors). In a recent retrospective report, DIC was found in 28% of those with NEC. 39 DIC is not specific to NEC, in that it also occurs in 16.7% of those premature infants with sepsis. 7 Circulating thrombin/antithrombin III or plasmin/a 2 -antiplasmin complexes are sensitive indicators of coagulation system activation.
7 d-dimers are sensitive indicators of fibrinolytic system activation. 7 In premature infants <1500 g birth weight with sepsis, circulating thrombin/antithrombin III (ATIII) and plasmin/a 2 -antiplasmin complexes are elevated in 91.8% and d-dimers are elevated in 34.8% of infants studied. 7 As mesenteric vessel thrombosis is common in NEC, one study addressed the question of whether there is increased NEC in children with the hereditary defect factor V Leiden mutation (resistance to activated protein C). In a study of 33 infants with NEC, the incidence of activated protein C resistance in the NEC children was similar to controls matched for gestational age, weight, and illness severity. 40 
Monitoring of Coagulation Disturbances
Normal neonatal ranges for routine coagulation studies are different from those for older individuals. 41 Compared to adult values, nearly all factors involved in the hemostatic pathway are deficient at birth. 7 In premature infants, levels of ATIII, a naturally occurring anticoagulant, were lower than in adults 3, 42 and lower than healthy children. 7 Physiologic levels of protein C (PC) in the fetus and newborn are low (0.1 to 0.5 U/ml) and may be near zero in the ill premature infant. 7, 41 Protein S levels are decreased at day 1 in healthy premature infants and reach the adult normal range by 6 months of age. 42 
Treatment of Coagulation Disturbances
Recommended standard treatment of coagulopathy, although not specific, includes administration of fresh frozen plasma and/or cryoprecipitate. 43 As the adult literature supports efficacy of antithrombotic agents, some centers also report routine utilization of heparin, ATIII, and/or PC in neonatal sepsis. 44 Studies of these antithrombotic agents in neonates are generally small and uncontrolled, but support that antithrombotic agents may have clinical effects in early postnatal life. Kreuz et al 44 reports the administration of 100 IU heparin per kg each day for neonatal sepsis. Activated PC concentrates are being administered to older patients with septic shock, showing promising results. PC administration to 12 patients (17 to 68 years old) with purport fulminates in an uncontrolled fashion resulted in an improvement in clinical status. 45 A large randomized trial of activated PC administration to adult patients with severe sepsis demonstrated a significant (19.4%) reduction in relative risk of mortality in the PC-treated group, compared to control, although a trend for increased risk of bleeding occurred in those receiving activated PC. 46 Infants have been included in reported studies of antithrombotic agents. Two uncontrolled studies administered PC to patients aged 2 months to 72 years with purpura fulminans associated meningococcemia and found improved hemostasis, improved circulation and/or reduction of predicted historical morbidity and mortality. 47, 48 PC administered to seven neonates with septic shock and purpura fulminans in an uncontrolled fashion resulted in improved circulating PC levels, with 100% survival. 44 In addition to inhibition of thrombin formation and reduction in levels of plasminogen activator inhibitor type 1, activated PC has anti-inflammatory properties to reduce activation/adhesion of neutrophils through decreased production of tumor necrosis factor a and decreased expression of endothelial E selectin. 49 ATIII is another therapeutic option that attenuates organ damage by decreasing microthrombus formation and endothelial injury. 50 In children, one uncontrolled study in four patients 20 days to 17 months showed that high-dose ATIII, without heparin, was safe and effective in treating DIC and organ failure, likely through improved organ blood flow. 50 A placebo-controlled randomized trial of ATIII immediately after birth in intubated neonates with respiratory distress syndrome conferred no improvement in lung function and was associated with a greater mortality in the ATIII group. 51 Although this study was not performed on neonates with NEC, the safety issues should increase caution in proceeding with trials of ATIII in adults or neonates with sepsis or in NEC.
Disturbances in coagulation are common in NEC. Owing to poor reserve capacity in ill premature infant, levels of procoagulant, regulatory, and fibrinolytic proteins are imbalanced, generally resulting in clinical bleeding. Treatment continues to be supportive, with administration of clotting factors. Conversely, microvascular thromboses may occur and contribute to organ failure. Advances in the understanding of coagulation opens the potential of better management of the coagulopathy seen with NEC. Further work in this area is necessary.
DISTURBED LEUKOPOIESIS Neutropenia
Neutrophilia with or without left shift is seen in less severe NEC as a normal adaptive response to inflammation. However, neutropenia is seen in severe NEC. Neutropenia was reported in NEC, with 14 of 40 infants in the initial study exhibiting neutropenia, which is defined as neutrophil count less than 1500/ mm 3 . 3 The mean neutrophil count in survivors was higher than in those who died, suggesting that neutropenia was associated with a poorer prognosis. 3 Similarly, Patel 4 observed neutropenia in 14/23 of those who died, but in only 6/24 who survived. Bone marrow studies at autopsy in a total of seven neutropenic infants from the first two published studies showed normocellular bone marrow. 3, 4 In infants greater than 34 weeks gestation, lower total neutrophil counts, higher immature neutrophil number, and greater immature:total neutrophil ratio at first presentation of NEC predicted which infants ultimately required surgical treatment of NEC. 30 
Treatment of Neutropenia
Owing to the association of neutropenia with neonatal sepsis and NEC, studies have examined the clinical use of G-CSF and GM-CSF in these conditions. In 14 neutropenic infants with sepsis (seven with early-onset sepsis and seven with NEC), G-CSF therapy was associated with a relatively higher WBC count and improved survival. 52 Over 250 infants have been enrolled in controlled clinical trials treating early-and late-onset sepsis, including NEC, with G-CSF, summarized by Kocherlakota and La Gamma.
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Although C-CSF was safe and WBC increased, no improvement in survival was seen. In a recent meta-analysis of randomized and nonrandomized controlled studies of G-CSF therapy in neonatal sepsis, G-CSF was associated with improved survival, especially when accompanied by neutropenia. 53 However, when the metaanalysis included only randomized trials, survival was similar between groups. 53 GM-CSF may also be effective in neonates. Controlled studies of GM-CSF in this population have shown consistently higher WBC counts, with a recent trial of GM-CSF for early-and late-onset neonatal sepsis showing both increased WBC counts and improved mortality. 54 In summary, disturbed leukopoiesis is commonly seen in NEC. Both neutrophilia and neutropenia are observed in NEC, with neutropenic patients suffering a worse prognosis. Studies of G-CSF and GM-CSF in neonatal sepsis, including NEC, report only limited improvement in morbidity and/or mortality.
ANEMIA Pathophysiology of Anemia
Anemia of multifactorial origin is observed with NEC. Of 32 infants with NEC 12 received erythrocyte transfusions in the 1977 Patel study. 4 Patients with NEC or sepsis commonly receive erythrocyte transfusions. 55, 56 Hemolytic anemia is common with NEC. Red blood cell morphology is consistent with thrombotic microangiopathy and includes teardrops, schistocytes, spherocytes, and acanthocytes. In the initial study, 25 of 40 patients with NEC had evidence of red blood cell fragmentation in the peripheral blood. 3 Several studies report that T cryptantigen activation is associated with extremely severe hemolysis. As high as 34% of patients with NEC have T cryptantigen activation. 57 T cryptantigen is a naturally occurring antigen found on human erythrocytes, normally concealed by a layer of N-acetylneuraminic acid, unless exposed by bacterial or other neuraminidases. 57 When this T cryptantigen activation is measured in blood, NEC outcome is poorer. 57 When blood donors have antibodies to T cryptantigen, transfusing infants with T cryptantigen activation may worsen the clinical course of NEC. In addition to hemolysis, blood loss anemia is seen. In the initial report, 12/40 patients with NEC had clinically significant bleeding associated with thrombocytopenia, with 4/40 experiencing severe bleeding that contributed to death. In the study by Patel, 4 platelet counts below 50,000/mm 3 were associated with clinical bleeding. Sites of massive bleeding include bloody stools, peritoneal hemorrhage, pulmonary hemorrhage, hemopericardium plus myocardial hemorrhage, and intracranial hemorrhage. 3, 4 Iatrogenic anemia may contribute to the problem, since frequent blood sampling is mandatory. In ill infants less than 1000 g whose blood volumes are less than 80 ml, phlebotomy losses may exceed 10% of the blood volume each day. Serial monitoring of coagulation studies using the standard 1.8 ml citrated blood collection tubes may double the daily phlebotomy loss. Anemia of prematurity occurs in infants at highest risk for NEC. Premature infants have an insufficient Epo response for a given level of anemia. When inflammation occurs, Epo levels fall further, with in vitro evidence supporting that inflammatory cytokines inhibit Epo production. 58, 59 In a retrospective review, infants treated with recombinant human (rh)Epo experience a lower incidence of NEC, compared to placebo. 20 Epo receptors are present on gastrointestinal epithelial cells, with studies supporting physiologic effects. 60 As Epo is present in human milk, it is possible that Epo plays a direct role in the prevention of NEC. 60, 61 However, erythrocyte transfusions produce gastrointestinal injury. 62 The beneficial effect of rhEpo may be indirect, that is, avoiding transfusion may prevent NEC.
Treatment of Anemia
Patients with NEC or sepsis commonly receive erythrocyte transfusions. 55, 56 With the dramatic decrease in the number of transfusions administered to premature infants in the last 10 years, 63 a study that addresses the number and outcome of transfusions given to patients diagnosed with NEC would be informative. A potentially lethal complication of erythrocyte transfusion may occur in infants with T cryptantigen exposed on the surface of endogenous erythrocytes if antibodies to T cryptantigen are present in transfused whole blood, platelets, or fresh frozen plasma. 57 Although no randomized trial has addressed this issue, some authors recommend washing or packing erythrocytes, washing platelets, or using low T cryptantigen titer plasma in patients with NEC in order to prevent hemolysis. 57 Administration of rhEpo to prevent transfusion is not generally a solution for acute anemia, as it usually takes weeks to improve hematocrit levels. However, administering rhEpo to patients with NEC may minimize erythrocyte transfusion later in the clinical course.
In summary, data support that the anemia in NEC is multifactorial, caused by hemolysis, hemorrhage, iatrogenic blood draws, and a relative deficiency of erythropoietin production. Treatment continues to be supportive with erythrocyte transfusion.
HOW NEC PREVENTATIVE STRATEGIES INFLUENCE HEMATOPOIESIS
Several treatment strategies have been shown to influence the incidence of NEC. The incidence of human milk feeding of premature infants is increasing 64 and human milk protects from NEC. 15 Although much work has been carried out, it is unclear just how milk protects from NEC. It is likely that many inflammatory modulators and anti-infective properties in human milk may work in concert to prevent NEC. In addition to the traditionally recognized anti-infective factors in milk, such as gamma globulins, lactoferrin, and white blood cells, milk contains many diverse hematopoietic growth factors. Although mechanisms are still poorly explained, these milk-borne hematopoietic growth factors may play a role in NEC prevention. 65 One factor, PAF-acetyl hydrolase, may play a role in decreasing NEC, via breaking down toxic PAF and preventing disease progression. 14 The roles of G-CSF and GM-CSF may improve leukocyte production and function, modify intestinal flora, or preventing bacterial translocation in NEC. 65 Epo may play a role because it is produced in response to hypoxia, has trophic effects on enterocytes, and stimulates vascular growth. 20, 65 The primary effects of hematopoietic growth factors may be directly stimulating gastrointestinal or vascular development (Epo), protecting from hypoxia (Epo), preventing translocation of bacteria in the gastrointestinal tract (G-CSF or GM-CSF), or preventing toxicity of an inflammatory mediator (G-CSF, GM-CSF, or PAF-acetylhydrolase). Whether these or other hematopoietic growth factors play roles in the prevention of NEC should be investigated.
Prenatal corticosteroid therapy is given to accelerate neonatal lung maturation and is associated with a 70% reduction in NEC. [66] [67] [68] Since prenatal corticosteroid administration may accelerate organ system maturation, increase cardiovascular stability, and decrease the incidence of patent ductus arteriosis, these effects of corticosteroids may contribute to the decreased NEC incidence. It is logical that anti-inflammatory effects of corticosteroids may also contribute to the decreased incidence of this multifactorial disease. 66 It is also logical that corticosteroids promote intestinal maturation. As the inflammatory mediator, PAF, plays an important role in NEC, the effects of corticosteroids on PAF have been examined. The activity of PAF-acetylhydrolase, the protein that breaks down PAF, is upregulated after glucocorticoid administration. 69 Similarly, the activity of PAF-acetyltransferase, the key enzyme in PAF biosynthesis, is decreased after corticosteroid administration. 69 
SUMMARY
NEC continues to be a severe disease with significant morbidity and mortality. Disturbances in megakaryocytopoiesis, coagulation, leukopoiesis, and erythropoiesis are commonly associated with NEC, and are associated with a poorer prognosis of NEC. Understanding the cellular mechanisms behind the disturbed hematopoiesis seen in NEC has progressed significantly in 25 years. Mechanistic investigations involving pathogenesis of NEC have implicated involvement of hematopoietic growth factors. Whether these hematopoietic growth factors have a direct role or are bystanders in the inflammatory process is unclear. Cutting edge hematopoietic therapies improve outcomes in other hematology diseases. Information gained from hematology may also improve supportive therapy for NEC. Additional collaborative research involving therapy for this devastating disease and its hematopoietic complications is necessary.
